⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ANEB News
Anebulo Pharmaceuticals, Inc. Common Stock
Cannabis Use Disorder Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035
globenewswire.com
ANEB
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
businesswire.com
ANEB
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
businesswire.com
ANEB
Cannabis Use Disorder Market Research Report 2025-2035: Pharmaceutical R&D Focus Intensifies on Targeted Therapies - Aelis Farma Advances AEF0117, a Selective CB1 Modulator, in Phase IIb Development
globenewswire.com
ANEB
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
businesswire.com
ANEB
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
businesswire.com
ANEB
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
businesswire.com
ANEB
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
businesswire.com
ANEB
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
businesswire.com
ANEB
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
businesswire.com
ANEB